Syndax Pharmaceuticals SNDX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Syndax Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's debt-to-equity?
- Syndax Pharmaceuticals (SNDX) reported debt-to-equity of 8.4× in Q1 2026.
- How has Syndax Pharmaceuticals's debt-to-equity changed year-over-year?
- Syndax Pharmaceuticals's debt-to-equity increased by 438.6% year-over-year, from 1.6× to 8.4×.
- What is the long-term trend for Syndax Pharmaceuticals's debt-to-equity?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's debt-to-equity has grown at a 402.4% compound annual growth rate (CAGR), from 0× to 5.4×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.